Literature DB >> 2384884

Single-dose kinetics of tissue distribution, excretion and metabolism of amiodarone in rats.

P A Wyss1, M J Moor, M H Bickel.   

Abstract

In order to better understand the pharmacokinetic differences between acute and chronic regimens of the basic lipophilic antiarrhythmic, amiodarone (AM), a mass-balanced single-dose study ([14C]AM, 50 mg/kg, i.v.) was carried out until total elimination had been achieved (10 days). Total drug, AM and desethylamiodarone (DEA) were determined in plasma, eight tissues and excreta of rats with constant body weight. Three exponential terms were sufficient to describe the plasma concentration-time curve of unchanged AM with a long terminal half-life of 131 hr. An equally long terminal half-life of AM could also be observed in all tissues investigated. After 5 min, 42% of the radioactivity appeared in the liver, where it underwent redistribution to muscle, skin and, ultimately, adipose tissues. Whereas plasma and liver contained mainly unidentified metabolites and little DEA, unchanged AM predominated in all other tissues. According to the time-integrated parameters of distribution, AM has a potential to accumulate in adipose tissue under chronic administration. In contrast, DEA accumulation would be likely to occur in lean tissues, mainly in the lung. In 10 days, 94% of the injected radioactivity was excreted in feces and less than 2% in urine. Almost all of the excreted radioactivity consisted of unidentified metabolites, indicating that both AM and DEA are eliminated by metabolism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2384884

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  The influence of hyperlipoproteinemia on in vitro distribution of amiodarone and desethylamiodarone in human and rat plasma.

Authors:  Anooshirvan Shayeganpour; Stephen D Lee; Kishor M Wasan; Dion R Brocks
Journal:  Pharm Res       Date:  2007-02-15       Impact factor: 4.200

2.  A Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data.

Authors:  Jing-Tao Lu; Ying Cai; Feng Chen; Wei-Wei Jia; Zhe-Yi Hu; Yuan-Sheng Zhao
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441

3.  Anticonvulsant and hypnotic effects of amiodarone.

Authors:  Gunnur Ozbakis-Dengiz; Aysegul Bakirci
Journal:  J Zhejiang Univ Sci B       Date:  2009-04       Impact factor: 3.066

4.  Survival After Intravenous Versus Intraosseous Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Shock-Refractory Cardiac Arrest.

Authors:  Mohamud R Daya; Brian G Leroux; Paul Dorian; Thomas D Rea; Craig D Newgard; Laurie J Morrison; Joshua R Lupton; James J Menegazzi; Joseph P Ornato; George Sopko; Jim Christenson; Ahamed Idris; Purav Mody; Gary M Vilke; Caroline Herdeman; David Barbic; Peter J Kudenchuk
Journal:  Circulation       Date:  2020-01-16       Impact factor: 29.690

5.  A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data.

Authors:  Samantha H Dallefeld; Andrew M Atz; Ram Yogev; Janice E Sullivan; Amira Al-Uzri; Susan R Mendley; Matthew Laughon; Christoph P Hornik; Chiara Melloni; Barrie Harper; Andrew Lewandowski; Jeff Mitchell; Huali Wu; Thomas P Green; Michael Cohen-Wolkowiez
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-02-12       Impact factor: 2.410

6.  Prediction of the dose range for adverse neurological effects of amiodarone in patients from an in vitro toxicity test by in vitro-in vivo extrapolation.

Authors:  Engi Abd El-Hady Algharably; Emma Di Consiglio; Emanuela Testai; Reinhold Kreutz; Ursula Gundert-Remy
Journal:  Arch Toxicol       Date:  2021-02-19       Impact factor: 5.153

Review 7.  Scaling basic toxicokinetic parameters from rat to man.

Authors:  K Bachmann; D Pardoe; D White
Journal:  Environ Health Perspect       Date:  1996-04       Impact factor: 9.031

8.  Neuroprotective effects of amiodarone in a mouse model of ischemic stroke.

Authors:  Masakazu Kotoda; Tadahiko Ishiyama; Kazuha Mitsui; Sohei Hishiyama; Takashi Matsukawa
Journal:  BMC Anesthesiol       Date:  2017-12-08       Impact factor: 2.217

9.  Amiodarone exacerbates brain injuries after hypoxic-ischemic insult in mice.

Authors:  Masakazu Kotoda; Sohei Hishiyama; Tadahiko Ishiyama; Kazuha Mitsui; Takashi Matsukawa
Journal:  BMC Neurosci       Date:  2019-12-21       Impact factor: 3.288

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.